Hot Sales
Perfluoro-1,3-dim...
|
DOPA-Phe-Phe-OH
|
Ethyl...
|
(2R,3R,4S,5R)-2-(...
|
1-(Benzo[d][1,3]d...
|
1-(4-Isobutylphen...
|
(2-ethylbutyl...
|
(S)-2-ethylbutyl...
|
Recent Browse
 |
Parameters
| Properties | |
| Specification And Standard | |
| Production And Usage | |
| Biological properties | PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4 cells at >25 nM and in addition to parental cells at 10 nM. PLX8394 effectively reduces cyclin D3 and cyclin D1, phosphorylation of retinoblastoma protein, and expression of cyclin A2 in parental cells and PRT #3 and PRT #4 cells. PLX8394 inhibits ERK1/2 phosphorylation and the growth of vemurafenib-resistant cells harboring either a BRAF V600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF[1]. PLX8394 significantly impairs tumor cell growth and suppresses MAPK signaling in LA cell lines expressing either endogenous V600E or non-V600 mutant forms of BRAF[2]. |
|---|---|
| Packing And Storage | |
| Safety | |
| Spectrum And References | |
| References | [1]. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May;27(3):479-484. [2]. Okimoto RA, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. |
| Contact Salesman | |
| Update | 20200220marketing |
